MPN Watch

Stem Cell Transplant Decisions

When and whether to proceed to allogeneic stem cell transplant for MPN patients. Centers on the upstream referral / timing decision — risk stratification, who benefits, when delay causes harm — and only secondarily on the operational mechanics (conditioning, bridging, donor selection) once that decision has been made. The patient-facing question this area answers is 'should I be transplanted, and when?'

PageMentionsLast seenTags
Pre-transplant bridging (ruxolitinib) 24 25-oct-2026
Accelerated/blast phase MPN pre-transplant bridging 14 27-sep-2026
Peri-transplant ruxolitinib for GVHD prevention 12 13-sep-2026
DIPSS scoring 11 13-sep-2026
Transplant underuse in intermediate-2/high-risk myelofibrosis 10 25-oct-2026
MIPSS70 scoring 8 13-sep-2026
Allele burden thresholds 6 11-oct-2026
Conditioning regimen comparison: FluBu vs FluBu+TBI in myeloid malignancies 6 21-jun-2026
MIPSS70+ scoring 4 11-oct-2026
Post-transplant HMA maintenance (oral decitabine/cedazuridine) 4 13-sep-2026
Reduced-intensity haploidentical HCT in myelofibrosis 3 20-sep-2026
CIML NK cell therapy for post-transplant MPN relapse 3 21-jun-2026
Post-transplant erythroid engraftment in myelofibrosis 3 07-jun-2026
CALR-targeted therapies and the MF transplant paradigm 2 25-oct-2026
TP53 mutation status as a transplant-decision modifier in Ph-negative MPN 2 11-oct-2026
Fludarabine + Busulfan conditioning regimen 2 13-sep-2026
MYSEC-PM scoring (secondary MF) 2 13-sep-2026
T-cell depleted, immunoregulatory-enriched grafts with RIC 2 05-jul-2026
Itacitinib (JAK1-selective) for GVHD prophylaxis 2 28-jun-2026
MTSS (transplant-specific scoring) 2 21-jun-2026
Gecacitinib (JAK/ACVR1 inhibitor) for aGVHD prophylaxis 2 28-apr-2026
CALR-mutated MPN outcome heterogeneity from HMR co-mutations 1 11-oct-2026
FLAMSA + Treosulfan + Venetoclax conditioning (FLAMSAClax) 1 20-sep-2026
CLAG-M or FLAG-Ida + TBI reduced-intensity conditioning 1 20-sep-2026
Clofarabine + Melphalan conditioning regimen 1 13-sep-2026
Tagraxofusp post-transplant maintenance (CD123+ MF/CMML/AML/MDS) 1 13-sep-2026
MYSEC-mPM / MYSEC-kmPM (molecular/karyotype-augmented MYSEC-PM) 1 13-sep-2026
Allogeneic HCT in MDS/MPN with neutrophilia 1 13-sep-2026
Atypical extramedullary hematopoiesis as an early-transplant referral trigger in MF 1 13-sep-2026
Pretransplant splenomegaly debulking in myelofibrosis 1 13-sep-2026
iCasp9 suicide-gene allodepleted donor T cells (CASPALLO) 1 05-jul-2026
MRD-guided post-transplant maintenance assignment 1 28-jun-2026
Hyperbaric oxygen therapy peri-allo-HSCT 1 07-jun-2026
Post-transplant pegylated interferon alfa-2a maintenance in myelofibrosis 1 07-jun-2026
CD8-reduced T cells for MDS/AML transformation of MPN 1 31-may-2026
CD24Fc for GVHD prevention in MPN allo-HSCT 1 31-may-2026
Decitabine + FLAG-Ida + TBI conditioning for high-risk myeloid malignancies 1 17-may-2026
Thiotepa/busulfan/fludarabine conditioning for CMML allo-HSCT 1 17-may-2026
Peri-transplant momelotinib in myelofibrosis 1 28-apr-2026

Ask across this area

Replies are grounded in all pages in this area plus every finding linked to those pages. Citations to findings render as [F123] and to pages within this area as [[slug]].

build build 612 · 69ce4cf-dirty · 2026-11-11